Psoriasis is linked to a measurably higher rate of nerve problems, though the relationship is more tangled than a simple cause-and-effect. A prospective cohort study found that people with psoriasis or psoriatic arthritis had a substantially elevated risk of polyneuropathy compared to matched controls, but the picture gets complicated once you account for the metabolic comorbidities and medications that often travel alongside the disease. What is clear is that the chronic systemic inflammation driving psoriasis does not stay confined to the skin, and the nervous system is one of the places it shows up.
The Epidemiological Link Between Psoriasis and Polyneuropathy
The most direct evidence comes from a prospective cohort study that followed psoriasis and psoriatic arthritis patients alongside healthy controls. Nine patients were diagnosed with confirmed polyneuropathy, while none of the control subjects had the condition, producing an eye-catching relative risk of 19. The neuropathy in all nine patients followed a classic pattern: it was length-dependent (starting in the feet and moving upward), symmetrical, and predominantly sensory, with minimal disability. Separate estimates for psoriasis-only and psoriatic arthritis patients were similarly elevated.
Here is where it gets more nuanced. Comorbidities and therapies known to increase neuropathy risk were far more common among the psoriasis and psoriatic arthritis patients than among controls (roughly 42% versus 4%). When the researchers re-analyzed the data after excluding patients with these possible contributory causes, the elevated risk of polyneuropathy was no longer statistically significant.1PubMed. Risk of peripheral neuropathy in patients with psoriasis and psoriatic arthritis. A prospective cohort study That does not mean psoriasis is off the hook. It means the disease rarely acts alone. Psoriasis promotes conditions like diabetes and metabolic syndrome that are themselves well-known causes of neuropathy, and it often requires treatments that carry neurological side effects. Disentangling the inflammation itself from its traveling companions is one of the central challenges in this area of research.
How Psoriasis Inflammation Reaches the Nerves
Psoriasis has long been understood as an immune-mediated disease centered on a few key inflammatory molecules, especially interleukin-17 (IL-17), interleukin-23 (IL-23), and tumor necrosis factor-alpha (TNF-α). These same molecules have receptors throughout the peripheral and central nervous systems, which means the inflammatory signals pumping through the bloodstream in psoriasis can directly affect nerve cells. A review in Experimental Dermatology noted that IL-17 and IL-23 can influence sensory signaling and may even affect the blood-brain barrier.2PubMed. Effects on peripheral and central nervous system of key inflammatory intercellular signalling peptides and proteins in psoriasis Separately, IL-17A, IL-1β, and TNF-α have been identified as disruptors of neuronal homeostasis, contributing to itch, pain, and stress-triggered flares.3PubMed Central. Neuroimmune Crosstalk in Psoriasis: Mechanisms and Therapeutic Implications
The traffic goes both ways. Nerve endings in the skin release neuropeptides, particularly calcitonin gene-related peptide (CGRP) and substance P, that ramp up the very immune responses that define psoriasis. CGRP released from pain-sensing nerve fibers can push dendritic cells to release IL-23, which then stimulates specialized T-cells to secrete IL-17.4Brain, Behavior, & Immunity – Health. Neuroimmunology of psoriasis: Possible roles for calcitonin gene-related peptide in its pathogenesis Substance P and vasoactive intestinal peptide do something similar, shaping dendritic cell behavior and fueling Th17 immune responses. In clinical trials, neuropeptide inhibitors have improved psoriasis skin lesions, reinforcing the idea that nerves are active participants in the disease rather than passive bystanders.5PubMed Central. Effects of Neuropeptides on Dendritic Cells in the Pathogenesis of Psoriasis This two-way loop between nerves and the immune system helps explain why psoriasis tends to recur in the same spots: the local nerve architecture keeps the inflammatory cycle primed.
Nerve Fiber Loss in Psoriatic Skin
One of the more striking findings in this space comes from imaging studies of the skin itself. Using three-dimensional optical clearing, researchers measured nerve fiber density in lesional psoriasis skin and found a roughly 74% reduction in fiber length per unit volume compared to healthy skin. The number of nerve branches (dendrites) was also significantly lower.6Journal of Investigative Dermatology. 3-Dimensional Optical Clearing and Imaging of Pruritic Atopic Dermatitis and Psoriasis Skin Reveals Downregulation of Epidermal Innervation This kind of small fiber loss is the hallmark of small fiber neuropathy, a condition that typically causes burning, tingling, or prickling sensations.
The finding is significant because small fiber neuropathy is notoriously hard to detect with standard nerve conduction studies, which mainly test large fibers. Someone whose electrodiagnostic tests come back clean could still have substantial loss of the tiny unmyelinated and thinly myelinated fibers that register pain and temperature. Skin punch biopsy, which directly measures intraepidermal nerve fiber density, is the gold-standard test for catching it. The 74% reduction measured in psoriasis plaques suggests that the disease is actively destroying small nerve fibers in affected skin, which could contribute to the altered sensations, particularly the burning itch, that many patients report.
Subclinical Nerve Damage You Might Not Notice
Even when patients have no neurological complaints, nerve testing sometimes picks up early changes. In one study of psoriatic arthritis patients, 40% had a mild but definite “glove-and-stocking” pattern of reduced sensation (hypoesthesia), even though they had not come in complaining about numbness. Reduced vibration sense was present in 20%. Nerve conduction studies were less revealing, showing borderline slowing of distal conduction velocities in 30%. The researchers concluded that peripheral nerve involvement in psoriatic disease tends to affect small fibers first, which standard electrical testing can miss.7Journal of the Peripheral Nervous System. Sub-Clinical Peripheral Nerve Involvement in Psoriatic Arthritis
A separate study examining 25 psoriasis patients with electrophysiology found that about 28% had abnormal nerve conduction results. The study also observed that as enthesopathy scores (a measure of tendon-bone junction inflammation) went up, motor nerve response times got slower in several nerves, and sensory conduction velocity dropped in the ulnar nerve.8Archives of Current Medical Research. From a dermatologist point of view, enthesopathy and peripheral neuropathy in psoriasis patients Together, these findings suggest that nerve damage in psoriasis can start before patients feel anything wrong, and that the extent of nerve involvement tracks with the severity of musculoskeletal inflammation.
Autonomic Nerve Involvement
Neuropathy is not only about numbness and tingling. The autonomic nervous system, which controls involuntary functions like heart rate, blood pressure, sweating, and digestion, can also be affected. A study of psoriatic arthritis patients found that half had dysfunction in at least two measures of parasympathetic (rest-and-digest) nerve function. About 19% showed combined parasympathetic and sympathetic abnormalities, and more than a third had moderate dysfunction of the sweat glands, a sign that the peripheral sympathetic nerves controlling those glands were impaired.9PubMed. Autonomic dysfunction in psoriatic arthritis
A separate investigation using sympathetic skin response testing in psoriasis patients (not limited to those with arthritis) found that the latency of sympathetic responses in the upper extremities was significantly prolonged compared to controls, indicating slowed sympathetic nerve conduction.10PubMed. The investigation of autonomic functions in patients with psoriasis In practical terms, autonomic neuropathy can manifest as dizziness on standing, abnormal sweating patterns, or unexplained fatigue. These symptoms are easy to attribute to other causes, so the autonomic component of psoriasis-related nerve involvement often goes unrecognized.
Central Sensitization and Neuropathic Pain
Beyond the peripheral nerves, the central nervous system itself can become hypersensitive in people with psoriatic disease. Central sensitization is a state in which the spinal cord and brain amplify pain signals, so that stimuli that should feel mild register as painful or uncomfortable. Research into psoriatic arthritis populations has found that this state is common. One cohort study using validated screening tools found central sensitization in about 35% of psoriatic arthritis patients, and those patients had higher disease activity scores, greater functional disability, and were far more likely to be resistant to standard treatments. Among those with central sensitization, over half screened positive for neuropathic pain.11PubMed Central. Central sensitization in psoriatic arthritis: prevalence, clinical correlates, and association with therapeutic refractoriness in an unselected cohort excluding fibromyalgia
A second cross-sectional study put the number somewhat higher, with 43% of psoriatic arthritis patients scoring above the threshold for likely central sensitization and about 24% meeting criteria for neuropathic pain.12PubMed Central. Prevalence of central sensitization and neuropathic pain in patients with psoriatic arthritis: A cross-sectional study This matters for treatment, because centrally sensitized pain does not respond well to anti-inflammatory drugs alone. If a third or more of psoriatic arthritis patients have this component, standard disease-modifying therapy may leave a large chunk of their pain unaddressed, requiring different management strategies that target the nervous system directly.
The quality-of-life impact is substantial. In one study, neuropathic pain scores in psoriatic arthritis patients correlated strongly with disease-specific quality of life measures and moderately with sleep quality and fatigue scores.13PubMed Central. Neuropathic Pain: Unexplored and Significant Relationship With Psoriatic Arthritis and Functional Parameters People dealing with both psoriatic arthritis and neuropathic pain were not just hurting more; they were sleeping worse, more fatigued, and reporting poorer overall functioning.
Carpal Tunnel Syndrome in Psoriatic Arthritis
Compression neuropathies are another route by which psoriatic disease affects nerves. In psoriatic arthritis, inflammatory swelling around joints and tendons can squeeze nearby nerves. The most studied example is carpal tunnel syndrome (CTS), where the median nerve gets compressed at the wrist. One study found that about 31% of psoriatic arthritis patients had CTS, compared to zero in the control group. Both ultrasound and MRI imaging confirmed that the median nerve was physically enlarged in psoriatic arthritis patients, even more so in those with confirmed CTS.14PubMed Central. Carpal Tunnel Syndrome in Patients with Psoriatic Arthritis: Ultrasonography and Magnetic Resonance Imaging Findings This type of neuropathy is mechanically straightforward: inflamed tissue occupies space in a tight anatomical tunnel, and the nerve gets squeezed. It is also one of the more treatable forms of nerve involvement, since controlling the underlying joint inflammation or, in resistant cases, surgical decompression can relieve pressure on the nerve.
When Psoriasis Treatment Causes Neuropathy
One of the more frustrating aspects of this topic is that some of the medications used to treat psoriasis can themselves damage nerves. TNF-α inhibitors, which include drugs like infliximab, etanercept, and adalimumab, are powerful and often effective treatments for moderate-to-severe psoriasis and psoriatic arthritis. But they have been linked to demyelinating disorders, conditions where the insulating sheath around nerve fibers breaks down.
A review of clinical trial data found that among roughly 6,990 patients treated with etanercept, there was one reported case of multiple sclerosis; among 5,204 treated with adalimumab, no cases were identified; and among 2,322 treated with infliximab, there was one case of demyelinating polyneuropathy. Outside of clinical trials, 19 additional individual cases of demyelinating disorders from TNF-inhibitor treatment had been reported in the literature at the time of the review.15PubMed. Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review These are rare events in context, but they are real. One documented case involved a man with a 15-year history of psoriasis who developed progressive right hand weakness and muscle wasting after cumulative treatment with both infliximab and etanercept for psoriatic arthritis.16JAMA Neurology. Long-term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-α–Blocker Therapy
A separate case report described a woman with chronic plaque psoriasis who developed chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a progressive nerve condition causing numbness in a glove-and-stocking pattern and difficulty walking, after 10 months on adalimumab.17BMJ Case Reports. Chronic inflammatory demyelinating polyradiculoneuropathy complicating anti TNF α therapy for chronic plaque psoriasis The working theory is that TNF-α blockers, by broadly suppressing a cytokine that also plays a role in maintaining nerve myelin, can paradoxically trigger autoimmune attacks on nerve sheaths in susceptible individuals.18PubMed Central. Neurological Side Effects of TNF-α Inhibitors Revisited: A Review of Case Reports
Another medication worth mentioning is methotrexate, a longstanding first-line treatment for psoriasis. Methotrexate interferes with folate metabolism, and in patients who already have vitamin B12 deficiency, this interference can worsen the biochemical pathways that support healthy nerves. A case report highlighted how the combination of methotrexate use, B12 deficiency, and impaired kidney function led to severe toxicity, underscoring the importance of monitoring B12 and folate levels in patients on this drug.19PubMed Central. Single Low-Dose Methotrexate and Vitamin B12 Deficiency-Induced Pancytopenia Causing Fatality: A Case Report B12 deficiency on its own is a well-known cause of peripheral neuropathy, and methotrexate can quietly tip a borderline deficiency into clinically significant territory.
IL-17 Blockade and Nerve Symptoms
If IL-17 is a driver of both psoriatic inflammation and pathological pain, then drugs that block IL-17 might, in theory, help both the skin disease and the nerve symptoms. There is some early evidence pointing in that direction, though it is far from established. Animal studies have shown that IL-17 promotes neuroinflammation, increases the excitability of sensory nerve cell bodies, and enhances the crosstalk between glial cells and neurons in the spinal cord. Blocking IL-17 with antibodies alleviated pain in these models.20PubMed Central. Interleukin-17: A Putative Novel Pharmacological Target for Pathological Pain
In humans, the evidence is mostly at the case-report level. One patient who had both psoriasis and chronic inflammatory demyelinating polyneuropathy (CIDP) was treated with secukinumab, an IL-17A inhibitor. Over seven months of follow-up, both the CIDP and psoriasis symptoms stabilized.21PubMed Central. Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated in symptoms after secukinumab: case report A single case does not prove anything, but it is interesting because IL-17A blockers occupy a different lane from TNF-α inhibitors: rather than suppressing a cytokine that helps maintain nerve myelin, they target a molecule more directly linked to inflammatory pain pathways. Whether IL-17 blockade turns out to have consistent neurological benefits in psoriasis patients is a question that needs controlled trials, not just case reports. But the theoretical alignment is compelling enough that researchers have flagged IL-17 as an attractive target for pathological pain beyond psoriasis.
The Skin as a Neuroimmune Organ
Underlying all of these findings is a broader shift in how researchers think about the skin. For decades, psoriasis was understood primarily as a problem of keratinocytes (the main skin cells), and then later as a T-cell-driven autoimmune disease.22British Journal of Dermatology. The biological basis of disease recurrence in psoriasis: a historical perspective and current models More recently, the field has moved toward what some researchers call the cutaneous-immuno-neuro-endocrine (CINE) system: a model in which the skin is not just a barrier but a complex organ where immune cells, nerve endings, and hormonal signals interact in tight feedback loops.23PubMed. Cutaneous-immuno-neuro-endocrine (CINE) system: A complex enterprise transforming skin into a super organ Under this framework, nerve involvement in psoriasis is not a surprise complication but an inherent feature of the disease biology. The nerves are part of the machinery that drives psoriasis, and psoriasis in turn reshapes the nerves.
This reconceptualization has practical consequences for patients. If your psoriasis treatment is controlling your plaques but you still have burning, tingling, numbness, unexplained fatigue, or pain that feels disproportionate to visible inflammation, the nervous system may be an undertreated part of the picture. Bringing up these symptoms with a dermatologist or rheumatologist is worth it, because the evaluation and treatment approaches for neuropathic pain differ from those for inflammatory pain, and addressing both components tends to produce better outcomes than targeting only one.